allotrap

Subscribe to Selected New Research on allotrap

15 relevant articles (6 outcomes, 6 trials/studies) found for this Bio-Agent

Description: RN refers to Allotrap 07; small synthetic peptides derived from the alpha1 helix of the heavy chain of HLA class I proteins; inhibits human T cell responses in vitro; prolongs allograft survival in rats and mice

Also Known As:

Allotrap 1258; Allotrap 2702; Allotrap E; Allotrap G; RDP58; peptide Bc-1nl

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Peptides: 16375

allotrap: 15

Experts

1.	Buelow, Roland: 4 articles (09/2005 - 12/2003)
2.	Fong, Timothy: 3 articles (09/2005 - 04/2004)
3.	Iyer, Suhasini: 3 articles (09/2005 - 12/2003)
4.	Luo, Yi: 2 articles (06/2008 - 02/2005)
5.	Lazarov, Mirella: 2 articles (09/2005 - 08/2005)
6.	Valdez, Marybeth: 2 articles (09/2005 - 07/2004)
7.	Belmar, Nicole: 2 articles (02/2005 - 04/2004)
8.	Buelow, R: 2 articles (11/2002 - 11/2002)
9.	Evanoff, David P: 1 article (06/2008)
10.	Liu, Wujiang: 1 article (06/2008)

Related Diseases

1.	Colitis 05/01/2003 - "The aims of this study were to investigate the anti-inflammatory properties of RDP58 ex vivo in human CD and in vivo in an experimental model colitis. " 11/01/2002 - "RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis." 05/01/2003 - "In rats with TNBS-induced colitis, oral RDP58 therapy reduced weight loss and diarrhoea and improved macroscopic and histological inflammation scores. " 11/01/2002 - "Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis." 11/01/2002 - "RDP58 therapy was evaluated in the dextran sodium sulphate (DSS) model of chronic colitis. " Order ALL the reference details at left...
2.	Inflammation 06/01/2008 - "In this study, we investigated whether RDP58 was effective as an intravesical agent for treating bladder autoimmune inflammation in a transgenic mouse model (URO-OVA mice). " 02/01/2001 - "The present study using Skh/hr hairless mouse skin model evaluated the in vivo effects of Allotrap 1258 on acute UVB-induced skin inflammation. " 06/01/2008 - "To determine whether the inhibition of bladder inflammation by RDP58 was due to the interference with effector T cells, we treated the cells with RDP58 in vitro. " 05/01/2003 - "Inflammation was assessed following 7 days of oral therapy with RDP58 or vehicle alone. " 11/01/2002 - "RDP58 significantly reduced acute, chronic and total inflammation scores. " Order ALL the reference details at left...
3.	Cystitis 02/01/2005 - "In this study we evaluated the effects of intravesical RDP58 on an established model of cystitis. " 06/01/2008 - "Collectively, these results indicate that RDP58 is effective for treating T cell-mediated experimental autoimmune cystitis and may serve as a useful intravesical agent for the treatment of autoimmune-associated bladder inflammation such as IC." 06/01/2008 - "RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model." 08/01/2005 - "Re: Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis." 02/01/2005 - "Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis." Order ALL the reference details at left...
4.	Weight Loss (Weight Reduction) 05/01/2003 - "In rats with TNBS-induced colitis, oral RDP58 therapy reduced weight loss and diarrhoea and improved macroscopic and histological inflammation scores. " Order ALL the reference details at left...
5.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/01/2002 - "These findings indicate that RDP58 represents a new, orally available agent potentially useful in the treatment of inflammatory bowel disease." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Dextrans (Dextran)
2.	Sodium
3.	Fluorouracil (Carac)
4.	irinotecan (Camptosar)
5.	Intercellular Signaling Peptides and Proteins (Growth Factors)
6.	Cytokines
7.	Protein Kinase C
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
9.	Nerve Growth Factor (NGF)
10.	Interleukin-12 (IL 12)

Related Therapies and Procedures

1.	Oral Administration
2.	Transplants (Transplant)
3.	Cell Transplantation
4.	Homologous Transplantation (Allograft)
5.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Colitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 575 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>